{"chunk_id": "The-Pregnancy-and-Lactation-Labeling-Rule-(PDF---656KB)__chunk_11", "source": "The-Pregnancy-and-Lactation-Labeling-Rule-(PDF---656KB)", "text": "• Drugs with systemic absorption \n– When use of a drug is contraindicated during \npregnancy, that information must be stated first in the \nRisk Summary \n– Risk statement based on human data* \n– Risk statement based on animal data* \n– Risk statement based on pharmacology \n– Background risk information in general population* \n– Background risk information in disease population \n \n*Required \nFDA/CDER/OND/ODEIV/DPMH 18 \nRisk Summary \nThere are no adequate and well-controlled studies of [TRADENAME] i"}